Effect of tooth extraction on stomatitis in cats: 95 cases (2000–2013)

Jennings, Michael W; Lewis, John R.; Soltero-Rivera, Maria; Brown, Dorothy Cimino; Reiter, Alexander M.

doi:10.2460/javma.246.6.654

Cited by 54 publications

(97 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most common reasons for study exclusion were manuscripts focusing on species other than cats (i.e., humans) as well as articles discussing treatment of other feline diseases, such as feline immunodeficiency virus, and mentioning stomatitis as a clinical sign or sequela. After assessing the included 16 studies, 4 were assigned an EDG of I ( 12 , 28 , 36 , 37 ), 3 were assigned an EDG of II ( 10 , 11 , 38 ), 3 were assigned an EDG of III ( 39 – 41 ), 1 was assigned an EDG of IV ( 42 ), and 5 were assigned an EDG of V ( 43 – 47 ). Seven studies (43.8%) were prospective clinical trials, three studies were retrospective (18.7%), and six studies were case reports presenting the outcome of one or two cats (37.5%).…”

Section: Resultsmentioning

confidence: 99%

Therapeutic Management of Feline Chronic Gingivostomatitis: A Systematic Review of the Literature

2016

View full text Add to dashboard Cite

Feline chronic gingivostomatitis (FCGS) is a disease characterized by protracted and potentially debilitating oral inflammation in cats, the etiology of which is currently unknown. The purpose of this review is to apply an evidence-based medicine approach to systematically review and critically evaluate the scientific literature reporting the outcome of medical and surgical management of FCGS. Those articles meeting inclusion criteria were reviewed and assigned an “Experimental Design Grade” (EDG) and an “Evidence Grade” (EG) in order to score relative strength of study design and produced data. Studies were evaluated and compared, especially highlighting the treatments, the outcomes, and the therapeutic success rates. This review found a lack of consistency between articles’ data, rendering direct comparison of results unreliable. The field of FCGS research, and ultimately patient care, would benefit from standardizing studies by adopting use of a consistent semi-quantitative scoring system and extending follow-up duration. Future researchers should commit to large prospective studies that compare existing treatments and demonstrate the promise of new treatments.

show abstract

Section: Resultsmentioning

confidence: 99%

Therapeutic Management of Feline Chronic Gingivostomatitis: A Systematic Review of the Literature

2016

View full text Add to dashboard Cite

show abstract

“…FCGS is a painful and debilitating severe oral mucosal inflammatory disease of cats that is estimated to affect 0.7%-12% of the general cat population [10][11][12][13][14][15]. Clinical signs are moderate to severe oral pain and discomfort, including inappetence, reduced grooming, weight loss and ptyalism [11,12,16]. Approximately 70% of cats respond to the current standard of care for FCGS, which is full or near-full mouth tooth extraction by either complete resolution (28.4%) or substantial improvement (39%) [11].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Efficacy of Fresh, Allogeneic Mesenchymal Stem Cells for Severe Refractory Feline Chronic Gingivostomatitis

Arzi

Clark

Sundaram

et al. 2017

Stem Cells Translational Medicine

115

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) have potent immunomodulatory functions and are a promising therapy for immune‐mediated inflammatory disorders. We previously demonstrated the efficacy of fresh, autologous, adipose‐derived MSCs (ASCs) to treat feline chronic gingivostomatitis (FCGS), a chronic oral mucosal inflammatory disease similar to human oral lichen planus. Here, we investigate the use of fresh allogeneic ASCs for treatment of FCGS in seven cats. Radiolabeled ASCs were also tracked systemically. Each cat received two intravenous injections of 20 million ASCs, 1 month apart. Oral inflammation, blood lymphocyte subsets, anti‐fetal bovine serum antibody levels, ASC crossmatching and serum proteins and cytokine concentrations were determined. Four of the 7 cats (57%) responded to treatment [complete clinical remission (n = 2) or substantial clinical improvement (n = 2)]. Three cats were nonresponders. Prior to therapy, most cats had increased circulating CD8+ T cells, decreased CD8lo cells, and a decreased CD4/CD8 ratio, however clinical resolution was not associated with normalization of these parameters. Nonresponders showed more severe systemic inflammation (neutrophilia, hyperglobulinemia and increased interferon gamma and tumor necrosis factor alpha concentration) prior to ASC therapy. Clinical remission took up to 20 months and no clinical relapse has occurred. A higher fraction of radiolabeled ASCs were identified in the oral cavity of FCGS affected cats than the control cat. The administration of fresh, allogenic ASCs appeared to have lower clinical efficacy with a delayed response as compared to the fresh, autologous ASCs. In addition, the mechanism(s) of action for autologous and allogenic ASCs may differ in this model of oral inflammation. Stem Cells Translational Medicine 2017;6:1710–1722

show abstract

“…Feline chronic gingivostomatitis (FCGS) is a severe, idiopathic, oral inflammatory disease of cats that is estimated to affect 0.7%–10% of the general cat population [6–10]. Clinical signs are moderate to severe oral pain and discomfort, including inappetence, reduced grooming, weight loss, and hypersalivation [7, 8, 11]. FCGS can be debilitating, and severely affected cats are often euthanized.…”

Section: Introductionmentioning

confidence: 99%

“…Naturally occurring diseases in client-owned animal species serve as useful animal models of human disease, as they reflect the complex genetic, environmental, and physiologic variation present in outbred populations. Feline chronic gingivostomatitis (FCGS) is a severe, idiopathic, oral inflammatory disease of cats that is estimated to affect 0.7%-10% of the general cat population [6][7][8][9][10]. Clinical signs are moderate to severe oral pain and discomfort, including inappetence, reduced grooming, weight loss, and hypersalivation [7,8,11].…”

Section: Introductionmentioning

confidence: 99%

“…Approximately 70% of cats respond to the current standard of care for FCGS, which is full-mouth or near full-mouth tooth extraction. The remaining 30% of cats do not respond to tooth extraction and require lifelong therapy with antibiotics, corticosteroids, and pain medication (refractory FCGS) [7]. Spontaneous disease resolution has not been reported in FCGS-affected cats.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Efficacy of Fresh, Autologous Mesenchymal Stem Cells for Severe Refractory Gingivostomatitis in Cats

Arzi

Mills-Ko

Verstraete

et al. 2015

Stem Cells Translational Medicine

104

188

View full text Add to dashboard Cite

The use of fresh, autologous, adipose-derived mesenchymal stem cells (ASCs) was studied for treatment of feline chronic gingivostomatitis. Cats received autologous ASCs, and immunomodulatory effects were assessed. The five cats that responded to treatment also exhibited systemic immunomodulation. Response to ASC therapy was seen only in cats with <15% CD8lo cells, suggesting relative absence of CD8lo cells may be a biomarker of treatment response.

show abstract

Effect of tooth extraction on stomatitis in cats: 95 cases (2000–2013)

Cited by 54 publications

References 25 publications

Therapeutic Management of Feline Chronic Gingivostomatitis: A Systematic Review of the Literature

Therapeutic Management of Feline Chronic Gingivostomatitis: A Systematic Review of the Literature

Therapeutic Efficacy of Fresh, Allogeneic Mesenchymal Stem Cells for Severe Refractory Feline Chronic Gingivostomatitis

Therapeutic Efficacy of Fresh, Autologous Mesenchymal Stem Cells for Severe Refractory Gingivostomatitis in Cats

Contact Info

Product

Resources

About